-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Gb2BCAKgaLiTfhm74rOVvKGa1dDegB7Mk81QAuxuk8F/DtDGLMkl05YyayW2aFf0
 OQphTeysJHiQQ9rBX+tvAw==

<SEC-DOCUMENT>0001193125-04-220264.txt : 20041228
<SEC-HEADER>0001193125-04-220264.hdr.sgml : 20041228
<ACCEPTANCE-DATETIME>20041228170712
ACCESSION NUMBER:		0001193125-04-220264
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041222
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041228
DATE AS OF CHANGE:		20041228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CURON MEDICAL INC
		CENTRAL INDEX KEY:			0001114365
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				770470324
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31519
		FILM NUMBER:		041229036

	BUSINESS ADDRESS:	
		STREET 1:		46117 LANDING PARKWAY
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		5106611800

	MAIL ADDRESS:	
		STREET 1:		46117 LANDING PARKWAY
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, DC 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%"
SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section 13 or 15(d) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>The Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Date of
Report (Date of earliest event reported) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>December 22, 2004 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="6"><B>CURON MEDICAL, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-31519</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>77-0470324</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>46117 Landing
Parkway </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Fremont, California 94538 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(510) 661-1800 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>N/A </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On December 28, 2004, Curon Medical, Inc issued a press
release announcing that on December 22, 2004 the Nasdaq Listing Qualifications Department has notified it that as a result of Alan Kaganov&#146;s December 1, 2004 resignation from the Board of Directors, the corporation was no longer in compliance
with Nasdaq&#146;s audit committee composition requirement. The press release is attached hereto as an exhibit and is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item 8.01. Other Events </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On December 28, 2004, Curon Medical, Inc issued a press release announcing that the Board of Directors of the Company, at a meeting held on December 16,
2004, appointed director Michael Berman to its Audit Committee, in order to cure any technical deficiency that may have existed in the composition of the Audit Committee since the time of Alan Kaganov&#146;s resignation on December 1, 2004, and
determined that Mr. Berman&#146;s membership on the Audit Committee is in the best interests of the corporation and its stockholders. The press release is attached hereto as an exhibit and is incorporated herein by reference. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item 9.01. Financial Statements and Exhibits </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) <I>Exhibits</I>. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT><BR><HR WIDTH="37" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P><HR WIDTH="54" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release of Curon Medical, Inc. dated December 28, 2004.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">CURON MEDICAL, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">/s/ Larry Heaton</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Larry Heaton</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">President, Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Date: December 28, 2004
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>INDEX TO EXHIBITS </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Index</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Number</B></FONT></P><HR WIDTH="33"
SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Description of Document</B></FONT></P><HR WIDTH="106" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release of Curon Medical, Inc. dated December 28, 2004.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>

</BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g16502image_16502.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B><U>Contacts:</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B><U>Investor Relations</U></B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Larry C. Heaton II</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Melody A. Carey</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Rx Communications Group, LLC</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">(510) 661-1801</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">(917) 322-2571</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>lheaton@curonmedical.com</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><U>mcarey@rxir.com</U></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Alistair F. McLaren </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Vice President, Chief Financial Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(510) 661-1802 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>amclaren@curonmedical.com</U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CURON MEDICAL RECEIVES NOTICE OF DEFICIENCY REGARDING AUDIT COMMITTEE COMPOSITION; </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>APPOINTS MICHAEL BERMAN TO AUDIT COMMITTEE TO CORRECT DEFICIENCY </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">FREMONT, Calif., December 28, 2004 &#150; Curon Medical, Inc. (Nasdaq: CURN) announced today that on December 22, 2004, the Nasdaq Listing Qualifications Department notified the Company that as a result of Alan Kaganov&#146;s December 1,
2004 resignation from the Board of Directors, the corporation was no longer in compliance with Nasdaq&#146;s audit committee composition requirement because it did not have the requisite number of directors serving on its audit committee.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Board of Directors of the Company, at a meeting held on December 16, 2004,
had already appointed director Michael Berman to its Audit Committee, filling the vacancy created by Mr. Kaganov&#146;s resignation and, the Company believes, curing any technical deficiency that may have existed in the composition of the Audit
Committee since the time of Alan Kaganov&#146;s resignation. Mr. Berman is not Nasdaq independent, because he served as an officer of the corporation within the last three years, filling the role of interim CEO prior to Larry Heaton&#146;s
appointment on January 2, 2003. The Board has determined that Mr. Berman&#146;s membership on the Audit Committee is permitted by Nasdaq&#146;s audit committee composition &#147;exceptional and limited circumstances&#148; provision and is in the
best interests of the corporation and its stockholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Curon Medical intends
to make a written submission requesting that the Nasdaq Listing Qualifications Department consider the appointment of Mr. Berman to the Audit Committee in its review of the Company&#146;s continued listing on the Nasdaq SmallCap Market. There can be
no assurance that the Company will be successful in maintaining its listing on the Nasdaq SmallCap Market. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(more) </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Page 2 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><U>About Curon Medical, Inc. </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Curon Medical develops, manufactures and markets innovative proprietary products for the treatment of gastrointestinal disorders. The Company&#146;s products and products
under development consist of radiofrequency generators and single use disposable devices. Its first product, the Stretta System, received U.S. Food and Drug Administration clearance in April 2000 for the treatment of gastroesophageal reflux disease,
commonly referred to as GERD. The Company&#146;s Secca System for the treatment of bowel incontinence received clearance from the FDA in March 2002. For more information on the Company or its products, please visit the Company&#146;s website at
<U>http://www.curonmedical.com</U>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This press release contains forward
looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, its success in maintaining its listing on the Nasdaq SmallCap Market. Forward looking statements address matters that are subject
to a number of risks and uncertainties, including the uncertainty of the Nasdaq&#146;s listing review and the corporation&#146;s continued listing on the Nasdaq SmallCap Market. Actual results could differ materially from those projected in the
forward-looking statements as a result of a number of factors. The forward-looking statements in this news release are made as of December 28, 2004, and Curon Medical is under no obligation to revise or update these forward-looking statements.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g16502image_16502.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16502image_16502.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2P#``P$1``(1`0,1`?_$`*<```("`@(#`0``````
M```````)"`H&!P$"!`4+`P$!``$%`0$```````````````8"`P0%!P$($```
M!P`!!`$"!`0%!`,````!`@,$!08'"``1$@D3(10B%18*,4%1D<'A,B,7\&%Q
M4H&AT1$``0(%`P$&!`4#`P,%`````0(#`!$A!`4Q$@9!46%Q(A,'@9&A%/"Q
MT3)"4C,5P>$C\6)R@I)3)#3_V@`,`P$``A$#$0`_`+_'2$'2$'2$<#W`.X?7
MZA_]_3_'I"%=;GR!U-GIMCA*_8W=6B*G*GC&3"/29>;U1J1,3OI(SMHNH[!Z
M=0#$2-_M`F)>P=^X]37%8>T>L$O+2%K6F9G_`!J8Q7%JWD`TG&5Z3R0T0N39
MA(1*H0,W=F4XK-3S%ND8QA@'P19BQ(."*(,ADSC]P)@`QDR]@((!]>K6-PUC
M_D'FW%!Q#:A('2HG]-(H]5<M8XRGDAH8YSJ3B;5_4\K2*XSFH67>(H@N121D
M`BBH2WVA"%>I-#J@Y`3%*H9-,Y3"(``A9RV*MF[MKTI(0XJH&@CT.+D:Z1@V
M/\B=7<:96XV<LCNS1-JGV40_C7:#$$T2R2WVX.HK[=NB=B9@93Y?`AA3,F02
MF`1_%ULLGA\>WBW%)2E#K;8(4-2?R,>!Q<]8\/1^2>MCH,X$/8EZW'0$[)1D
M="(-V2C3X(I\HU$9@CELHH^<.?@$RA3F`"@;L0``._5RTP>,^Q!5M6O8#N,Y
MDRAZBYZPRK-;0ZNM!J5L>M`8O)Z#8R+EL7R^--=9,/E,CY?B^W6.`G3[]_P&
M#ZC_`!Z@]TTEFX6T@S2DTC*024`G6,WZQXK@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0@
MZ0@Z0@Z0@Z0@Z0@Z0@Z0@Z0B%?++F[F/$TL)'65A-6^Y61NM(15-KIVB#I*(
M05^V4F)>2?'*TBX]1T`IH_11990IO`@E(80WN"XSD<\\IQA246R*$G29_,Q;
M>?0VFNL::Q;=^*/-9.T6Z4JK^HW.A1(SEUA[)(J1ZH5=HF8/U">4A7:<?/0L
M>"/QJ*B!%VP@!5"`!B";99/&<AXNI%BVL*:?H"#V]G8?C%EMYEP;B*Q'VT^S
M;B/:9-GFTSD-S>Y/$/4V43>&:3!C^5M4"F;%FHJMMG+:Q-8LJ0=Q`J@.5$![
MF0$WX.L^WX;F[%@Y%JX0;N4U(U()K(F1K*'K,&DJ1*#9^2_&'AQG-=0CZZ>Y
M!K,3^>5ZL5TR#]U<*TX;(@-@G)J;5,@W@CMWI4TA5\S'.<2II#V4$NIQN)Y#
MR:^<)('IJE/0)(Z`?I%;CC*&PJ0J(Q#A7O'$_:9:S3%)IDCG&A4R-<STE`7.
M1-)$C:WV%!W8*S)?=N(U1@T!8".1`J2[4JA?P@F8IAN\BQO(,>TBWO%^I;J(
M0D@T5V!0_+PBBW=86A1`TB-M[]A/"V?UI5P]QN]6*O\`YF1O):/&K-H]A,_$
MJ*)YD:8$BWD99@(_B`Y_A<N$NP_&(B`=;YKB/(+7&S+[*7-O]N4]M*"?A+ME
MVQBFZ9[/QX0[FGSE<LM4KEAJ#QC(56:A(R3KCV,`"Q[F$>LTEXQ5F0"D^-`S
M0Y/$@@42!^$0`0[=<X=;?9=4U<_WTJ(5XQL6U!2`I/[2(R/JW%<'2$'2$'2$
M'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$(\]HW$'7]1O=:VC*JQ(7U
MLC5&E0LU;A@36L,6>)D91^PEH^.6425DH]VE*F35(W\U4U$P$2F*;N7I'",]
MC,>TY89#:GU#,*/Y3Z1K;UA:_,DF,)X%\#-=90^WV+6(J0S1+1\>M>1U>%EO
M%.P&/;2MC/;'*QS94ZS".C_L$2)(K"5=83G$`*!0$;_-.38=YZT8Q9+BT*"E
M$5``.@/2*;.U)947-94G^<0'5]?G+Y"\?\?EQN=4<@_^P);$SL1H`M05%,DP
M-G%R5DG&"D4%!*;LZ*7\/Q^?8.I*CEN$38*N&G0AXI_;U49:$:DQC_;/`RK$
M_><G`G6G=(P"4RJ+>Z:ME.1P>2VJ&A_$9LXP2JKYM8H:-=*IG?,G3I^Y3402
M$5D2E2$"F`3>,:XORFP;N[M62_XB^LJ04^4#I(GX1>=MG/23M)-*QX/K]X)Z
M_'2>F7?6H&3S.*LF4W7+J[%S!"-[*^<7MBC'R4TZBTU3+L8V':I#\15_!59<
MX"4`*01&WRKDN+-LU:VA+KOK)6LBJ1M,Y#Q_6+EC;+#*BK4@Q!21]>W+V)NQ
MZ"CCL[+G(^_+VMOCC,1HKYG\OPMYG]1J.2M&+%5+LJ=-?Q<IE[E%(3?09JGF
M.!=L#<(N&VG=@DV4S5,"4CU,8ALW>R+1G'W,E<:Q/,<N<OR2CRDU")A'[]+R
M!!U(HH_)(J-0.`'*S^^54!$!`!!("@/7#LI?')9!V^(`]1<Y`2'9I\(V]NCT
MV4H.H$;AZP(O0=(0=(0=(0=(0=(0=(0=(0=(0=(0=(0=(0=(0=(0=(0=(175
M]Z/._:^/CC,,`P^SRN=R6AUB7O5UOL`K]G92U]I+#`1%:KDJ!#K01WKYLY6>
MNT/%U\1$DTSD`YQ'J?MIQ>PS7W.1R6U3-NH`)4)I)(G4&AC19J]7;)2EM123
MK+6%!^NSV2<G<EY*9;6+;J]]U/+--O\`6J-<Z9?[#*W0$$[C--H)M9*P\G7#
M^3A)R&?R"3D006*BZ1(=)4INY#%G7*N&8*\PS]S:,,VUU;L;DEM(1,B>LM9C
M_:,&TRBTO(0\I2@YH"9QN#VU^Q7D?8^4VH89G.E73*,JQB>+24H>A3;^IRMN
ML3%DR<3UBL\[#+M)9XA^9+&18M`6(U3;I`H)#**"?K#]ON&8IO#M9?(MMOO/
MMS`6D*EYE`2G/\&*\I>/I=6Q;+4@I/\`$RU`[(DIZ;/9#MLY9M.Q+>;;:=<K
M-:R"Y;#3;!87JLS<X(<[1:NI^K+SRXF?2\3+QCD#M/NS*JM7*/@0XIJ^!-/[
MC\1Q;-O;Y+'I0P^70A2$#:%!=$G:*3'U^`BK"7UR5*MWYKV(U-3/7K"?]G]D
MO,?<-(D--<[WIU$37E%9&IT[/+E/5"ITJ,%<ZL7%143"OF:#U5@V^,BKIX5P
MX<J%$QS"`@`=$Q7!>.XNS%LY;V]P\IL!2UH2I0)$S4CM)C7&^NW25%:P"329
MI6'BXY[;-J-ZLMDV>R@UL?(#(+Y7L5@[L]C&QF$T]O:<4K6+O8HIL1M'NYFO
MQSUR#@A$TT7CAJB8Y.ZQRCR[(\!L6N;6V)9<",=<CU:4`"9E2>X'\=(VS.2N
M$8QQR1+J52GVSZPA>N>PCG#6-"1TYAR@V!_:DWI7SA*?MLK.5B5$BORFCI2C
MOEE*LO#+B'@+0C1(B:8]DQ3$I3%ZW=<0XS=6WV:+.V1N;(2H-I!ZUW`3GWSG
M&H;R5RFX+KBU;"=)T'PB^CQ/VM3D;QMQ7<EX@L"\TS/X&S2<,F)S(1LNY;?#
M,-69E#'4.P3E$%OMQ,(G%#P$WU[]?+F:QIQ&6?QI5N]%PB?:-1]#$PM7A<6Z
M'DZ*$2$ZU<9$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$>HG)Z&
MK,3(3]BEHJ`@HENH\E9J;D6D3$1C)(/)9Y(R3Y5!FR:I!_J.H<I0_F/524+6
ML-M)4IQ6@`F8\*DI!6Z0E`ZF$U\SL#X=>VJ#C(/&.4&-R>\Y.27-5IRA7FJ7
MY1&'D3H'FJ]<:Y7YQ26=5AT\9HJD<H`"C)P7S()@.=,\WX_F,YPEQ3][:OC#
MNF:PI!"21IMFD@D#PGTTC4W#-IETCT7$%:?C_P!(C/PH])##C+I\9R$Y2Z[0
M[0WRA\6VU6!K9'D128Z7B?D79VZ\62UIQ9OMZ\L`.6[0$TT"K$(HLJ8$P(.\
MY+[D#-VJL7A6'6P]($D#>4R_;M`)'_N\!%BVPR+=S[B\4G:DS`(H/B=(Q;F/
MP#XP>QC:Y[4.&',#CPYVR83;&U#/V%\@;I$6%Q#,TX\+:T0IDG*6&'ERQ[5%
M%Z8&CAFX^(J@BDIY&4O<>Y=EN*6*;3/6ET<:VKR+V5`UV5&DS,5IV&+5U:6N
M2>]6S?0'":CJ?K.)O^NWU>4'@/"7;0]+N\%?]0ME7>5^V6E=N$'G].H/RD?2
M\)$EF505.QE#M$E9%^]%(52(D(5-),IA/&^5\TN.6/-)L4*:M6U`I$@I:U`F
M1)`!!&@3,RU\-CC[)%BA:GU#U"*]WQ,)RMOJ(P/>MTG8GA!SMXRV*JO)%Y)K
M9@YO,;=[Y1$#N5'$A&PC>ERDFM9Z_$E$2-CK%;*))"5-54XE!49[:>X>0Q6)
M0K.8^[%R$RW[2$N=)DRI3L"M)QJ%6#+[G_UGD%2CH9"7UK\H>_1/67QPS#@]
M<.(-@>O)6CW%L]LVE:3).&$'/.[HF#%ZGH2#I7SCX`:LM"M3,$3F.W;MVI2*
MBJ!E3'YO?<PO[_DB,ZS-+J*-M":@$?TFE9UF9=>Z-XBP:;L3:.J`)%3+K%?G
M&O3QCVL[FM0J_P"Q3C%IU,C)9R>2K^36V&G-NDX!DH<RS1"LM9B0AXR34;)B
MFN[26>HMQ$5"IF[`7KJ%_P"XEU:8GUSCKQNY+<DE21Z:9]4K-9=9;4]12-"U
MC;=ZZV^LA4OXRU^9_6+A^=T2JY?0Z?G-&BD8.G4:N1%5K40@)C)L(:#9(Q[!
M#Y#_`.XLH5!`!.H;N=0XB8PB81'KA5U<OWEPNZNE%=PXHE1-9DQ*4-AE`:2`
ME(Z#01F75B*HZB80'MV#^_\`AV'JE14);0".M92_6/!N/2D'D/\`0/[_`.70
M*"JHD8],YR`@\O\`M_Y[#WZIW+[!3O\`RI'LNV#R^G<`_P"O[=>I45`TD8\,
MYR&L<>0]@^@=_P"';R_RZ]25$5EOZB>D>>;LCGR'O_`/[C_^#U[N'4'Y1525
M8Y[_`-?I_P!?]^W7M#I'D<";MUY4Z1Z!..H'$3"7Q'M_[?U^G].W7O29(G%1
M2`)SK'81'^0`/U_F/;_`>J%*4"-@!K6ND45CCS^G?Z?W^G]^W5R1^,>>8TE6
M.Q1\@[_Y_P"`=4UT(D8]KUUCGKV$'2$4K?W3O(34$M.P/BNQEY.&QV1SAUL-
MGB62Z[1E>[<O:Y:L1"4[\"I"RT;4&4&*J#53ND5T^%4Q3'(D)?H'V5P]FNWO
M,V6T/WS2@E*5?Q!$Y]?H*@:Q">47-SZR+9,TV\ID]IBJ=0;_`'7&[O6]4RZS
M2E'T"B2C6R52T0#E2.DXB6C#`Z06(LU,D*S-;XOC7;*`9!=N<Z:A3$,(#W&]
MQEKF[=6/OT)<:="@00`!Y9[T_P!,M)=TYQ%K919?;>9W;R:B9[8LX?N$>9.V
MZ'DG`/+G2TA2Z+O'&VM\E-5KL:=U',;;>IQG"H-*U,)E4*#Z"J"RZSHC%7R2
M%9VBH<IC))"7AWM3Q['LWN3O4-I>N[2Y4V@*KY03YIUKX#02B3<CNKQQAA(F
MEI:9J'8?I%8*G6ZU9=:J[HV<V*4I-\I4LSGZG;:V[5BY>`E8]4B[1TS=-S%4
M!,BA`!1(1%%9(3$4*8AC`/<;EG[W=:724/LOH*5-D!(/E_>#64M)=TYQ#TS:
MO&W6=P<!K(FOZ1:(]]'-G==,XI>NBCO7$E2ZUR9X^Q/('9X^(^XB6ETMA8>G
M%85=^5%0@JUR&D9MQ(FCC"9)15PV,H!@1)UQ+VQXQCT9G*7+80XNSN%(;"A.
M0F:S/6DCX&)?R*ZNUV;"VP4[T@J'ZFDXJXU6PS^?6:"O-$GY.FW*IR36;J]I
MKKU:*FJ_,1ZA7+*0CI!FHDX;*MU2`/8#>)@_"8!*(@/;GK1-_:N6MZE+S+C9
MFD@!*?`5\8B3>YB\2ZC<ITFM2/UBTO[N><^^Z;P)];-<D',I3HSE?BY=AW0(
M<%8EO>IR`A*2BRK;K[<R0A6GDG8W$PHP#_97\VP'`2)@`\.]M^*XU'*,G()=
M79ND-@@$2F2?B*"?=XQ,,]?7GV#!0"E2Q-5?S_.*LL#-S-,G(6U5&8E*K::S
M),IBMV6O/%(F=@96.7(Y8245)-#HN63IDLF4Y3D,`_3MV$!$![P\VG*VRK*Z
M"%6RVCN24B0U%.R(D^M#;S;Z%*^Y$MU=3'U4/7GM-TY%<'^+FW:,@"-[T?&Z
M?8;:H5N#0DA.J,"M9":3;%*0C=.?7;"]*0H`0I7``4/'MU\1\GQ]OBN07>/M
M?_SM/$)\*&7PG*.L8]]5S9-OJ_<I/^T3&,82@8>W?Q[?3O\`Q[__``/\^M#T
MC,-!.$X7#F#O'*OG!J/!CA19:UEE4XO0==E.87*Z=J;/192KW.YIG=5+!\2I
M<LY0J3N_.(QLJZEYJ:*]8Q1$CHE9+KD[#,&L+9XW`LY[-H4X]<K4&&0=H4A(
M$W5*D52G3:`.E:TU:KQZZNE6-MY0@>9?93H*3K3YZ2K^?*^R<^>#6/SFT9SL
M;;F-3HY_4X:[U;;J)1JC?LWC;/;X&M.]9IMEQZN4F%N$'2T)91U*5R3B@669
ME,NWDD?@,BOBXEKCV;OOL[N=B2A2DK3-P*(!(00HB4R/W3[!**+A5W9V@=;6
M7:RF1+KK3Y2^,83[3^0/,+CCN7`2N\?=YKU/I_+[EI3^-=RK]JQVG7E6F1D_
M'E?K6RGR[DT;(J2X-XYUW0D3NVXK.$Q#P(F)#[+B.'Q.9QV3?R#*B[862WT$
M+(W;52"30R!F#,:=AUBUE;BYMG[=MI?E<7MJD&6E:COZ2AOLQ4;T\S?])Q&K
MRT+>0CD&R>I_I.FR4D:134`ZDDXJ;F*)4E"N^PE.@FW2(!!_`)#=C!"T*8^Z
M]5UO<S3R;B/A.I^,;AU+JV]K:]KG;('3N-(@9Z[[+R?Y"\+*IK&T<A$I'5=4
M;V4[&<I^2Y_68+/S5O0K35VQH.N.6<TE-J24;!)"Y_,UG)04.842I?3J0<AM
ML5C<VNUL[<BW;""0I9)5N0A1!(`E(JI(1B8Q5RY:^J^X%+7/1($I$CIKIUB"
MOKMUKV6\W<AY)71YS-SFEW_#^5V]<;ZQ$GXJ4J6S^SAC[Z+8P4];4VUIB[6@
MG8EGA@?)Q[U`S=/L9$PB'89+R['<8XW=6EI]L^M-U9,OD^N04^J3-*4E!"ML
MJ$D3/9&!C;F]R#+BVG`DMK*9%`U`GJ"*&?9\S$FN#?M@K>Y<`-?YA<FH*$QV
M0XJ6[7LXY))U=P^F*<2UXLHW+,R^='?F&3D(NV)/VOY:R545<E=N`;"HH/BH
M;59_ASV,Y$QA<82\S=LMNL$T44N3HH=-I2KOD)RK*+]EE$N8]=W=R2IM6U4J
M@FDI4&LP.R>E(Z\5I_GCS_S*O\H[;M#_`(.XYK#0+7A&#Y1GF;W/6RY?(BHO
M3;EMNG:W7;W#C9[A%&2?A#04,Q:,&JR9#NG"AC"2QFV<)QZ[.)#?W=XUY75J
M60V5]4H0B1&V>TDJ-08KMC=7UNFZ#GIA<R$@3D)R%3(F<IZ#6/46'F#R!X$\
MJ,)P+FM<JOM7'/EC9U<XP7EI&4Z.S2YT+:OB26BL@W^HU]8U&D6=T2.4(2R0
MZ,40[D#I.610**I?6<!C^18NYR.&:]'(6"0MQD**DJ035:"?,)=4G=UD=(H<
MO'K*]:MG_,TXD^?]LB#I+KTG4'K4`QJ_V9<YN7/KRY(87HE;;+\@>'\W5M-T
M+E)E<9GM>_Y(R')J/.9O59/4*!:(=6/FYV/ISO1V[QZT?(NS&00.*BR:9C*H
MYO%^-8OE&,N6G5_;9+U$(843Y775!1V*%`FB:*KX4K1?7ES8725I\[*C,B0&
MT:4.I_'2&+;?K\GIG"6V\E.(NZ0L6V_X1M>VY;HD96:YH%3ML?"T:9LL(PE(
MBP(&$8E^Z:)D>D14:2#<Y#I"=-0IR]1>PLU6^<1BLLRJ9=2VI,RDIFI*:'XS
M'0B49S[YN+-5S9+T05`R!F0#2O>)1L_B"YU"8XZ9';]BT<NFWZ_Y[2+[/3C:
MH5VDQ3)];*G#33R&@X*NHE31AV#QVH"!G*KET8@_C5-V#M[FFK:WRUQ;6:/3
MMVGEH`*BHD(44S).I,IZ`1<M4NAA/KJWND3)D!7P'RB2W6KC(C$+QH%'S.MR
M5RT6XU6A5"&3^66M-TL,55Z[&)C_`*3OYJ;=,HYJ!OY>:@=_Y=>,)?NKD6MH
MVIQ?7:"2.Z0UBAQUIE.]Y02GM-!"6^:7'CUX>[BIQ-+SOE7D<SMN3*3#ZA7S
M&K[1M!M-:92:;<)R$LU.930/+'1Y91BBJNF!D#-W*!%4%TS`<%.A\<S7)/;^
MX^_<M'A9.B2DK"DI6.T&1D:RT,XTF1M\?GF#:M/A+R3J)$_*D_A"WN-/[6J!
MJFFPUIY0<BH_4\]KLJTE"YMG=-D:J6\%8N2ND(RVV":F9%RP@71T^SQLQ2%=
MRD(I@X3`>_4RS/O4JYQR[7%6BV+E5/56H[D3U"4@5\21W]D8=EQ86[P>==FE
M!TEJ/&&"^RS,/5C[!:_5>.%_YF<=\DW?+I)=OD<M7M8RP]IHS]XV;Q3^DOZF
M\L+9M*UJ52CFR2\0*C5<BS9(R)TE"?BB7$+[F'%[I6;MK*Y?QS@FY-*PE8KY
MI[3(]\C/Y1GWZ+"_:5:%Y"70:5$T]WA"[..O[6*%A-'B+!R2Y,1VE9=#R#64
M"B9K3)&L/+VT;J@LE&62S3$Y*&AX&12`I7*;!)1=9(QB)N$_(#A*\O[U>M:J
MML5:J9OQ.:W%51.D@D"LN\CPC66W%6VWTW+CVX3!``$C\9]?"&K>W/CCZ[]Y
MQ"D9!RJY#Y-Q3L-#,1]@ESFKM1JG-TXOY<E"*Q<=4['*QPV2B2,>R0;NV)02
M3'[9(Z:R2J1#!!^$Y?D^-R:[[$6]Q=H<5-T)"B%S).H!D:FM>L^[;9)BU?9]
M!]Q"%`4K44A,?$C]M%E&BV*$TN[<WZ!R$X^)22;A-IQZCVRI+^W:F165A)>^
M)VJQ1M>;ND3@5X1B5=V"9Q*FHB8P'+TCD/O%>M-.8UK&N6F14@@^J5#:=)@;
M1/NJ(T>/XRTI_P"Y]=+C8-`D`_/L^4/]]E?`CB/RHXJQ6;;I;:_Q\IV-$8O,
MIUP)*N5B/QQ>/B"0#1F16S.F,"[J;V&02:.XQ==$KI)%/P435334)RCB/)<U
M@\W_`)''I5<W+JSZC=?^29K5()!GUD8D.0M+5^W].X5Z:!H3*0\)FOAK%:?A
MIZ#>*&ZZN+=?V:X-R,HE9?E?3&><<)&OJZ'8X=BL0ZS"6=C<[`O5(QXB'@Z<
MLVCHQ2&,"2J9A*<O7>1>YV9M+-9:Q5S;.NIV[G9A*21*8,JU/4IG](CMGQRP
M=N-Z7TN!)T$IGQK3ZQ>`I]4K=#J=:I%.AV->J5/@HJL5B!C$OACH:`@F*$9$
M1;)+N(IM6#!LFD0!$1\2AW$1Z^>W777W5/OJ*WEJ))/4DS)B9H;#2`V!()$I
M1D!@[?B[_P`P[_\`@!^O5E0)$IRK.*YTE%<GU)LE<#]F_NDXRZ.HI':5H_(*
MM<N\Y5EO%!WH>*:.WGRMIZ`,MX'F(ZHRDDC'O#H?(FU=JBD;Q,`AUU#FCO\`
ME.)8/*V^W[2V96PL)F?3<GHJFI`G&AL?^+(7+"II<<5N3/\`D*SE\_S[(<9S
M,Y*9YQ0X^7#8-+:1,S",Y&IT^'JDH]9,_P!<V^_VJ'IU4I[(K]!VDZ>2TO,I
M]TRHK&*@FHIX"4AA"`X7%W6<RB+"S!#IGY]9)"221+PE66HC97EQ;VUM-=:R
M`[3^)GP!A5OO".%=T3T_Z9-F+'43//:7B0W.SNC?%%5Q"QP\_%0SV9>J^+>/
M9.Y,H(BLJ<B93F*`CW$`&:<`=3]CG;-`*KIW$K2@?U'<)^/P[8T^9\J[5YR?
MI-O>8RT_:9^$NL/JDI5A#1TA,3#MK%Q40S>2<I)/ETVS&/C8]NJZ>OWCI8Q$
M4&C5JD9110P@4A`$1'L'7.4;EOI82"I:R$B4C7PZ5,HDJI)25`@B40!]3[!Y
M'^O+C"=ZW6:_G51G;9'$<I*-U5X&ZWZV6^M/OB6(FH5.3K\XU<$[@`B14!ZD
M/,7V#R)\H6#_`&TCO*6VTJ'P4"(PL<A2+1"5:@*/S)_6*OV!S'-G*>%G/GD)
MQFV#1V&19][5^7@<I<6R6DYJYV)YA)[5#HZ!I6!Z'9JC9YF!T^J1CL'IT%T7
M+3[!J=5O\"R8F-U[-L\>O>0V.-OVVE9)S#6_H.K<7L2Z$DI2M$@-JM!76?:(
MB=D+NWLWG[594E-P=R)`4F)G=4R`\.V=*M`Y2<0\$T?]O-L>-^L;Y+CEUNR1
MKM&?/82:=7"W:[+0]PK^H75>VS!SJRU@TNUE@7*+]%<"N$Y%(K3XDP3*F2)X
M3.9"V]S[:^YA)#P<]-8(VI;3MVIVB4MI!!'21G,S)C97MI;N8-2+":VPH*_[
MII4"JG:F4I=@E#;_`%L;?0N07`WB;IN;OF#VN26$YQ"N&K!9%3].V.HU>,JU
MJJ;])(1^PE:S8(EPS7;'`BB1DNPE#Z=0?E-LNPY%>L/@;Q<K(,]4K)4DS,IS
M20:1M\8^+C'M+0DI.R4NS;Y9?3Y0I[]P4V7WJ0]<?!O.4TY?>MIYOYKJ,*PB
MQ^YFJ-EN/MI5Q?=/E4&HJ/(BM0Q)HGD]4(5$QD3D*83$$`FGMHIBR&3SF0)1
MC&K!Q"N@<6H>5`/4Z2C5Y\&X]&S9K>%4_P#Q%1_O\#V0S_5HV-G/8CQIAYAD
MQE8B8X@\QHV4BI)L@^CY.,?W[B\U>L)!BY(=!VQ>-5C)JI*%,0Y#"4P"`CU#
M+-YU/&+AW<0$WC2@10B2792^$J]T;1T(5D&TFH+9!';^*PA[=D9_T:6+<\+7
M/+2/JAYR4C<H_&Y5W]Z^9\(.3-QH-E4+F;I^8ZXL\>T^17[QA#@`-7!NY1$Z
M#DSGI6.::Y^RU?-;4\PL5-%::#[II"D^>=)+2D`;0#.M?-32NN*P[JV*_P",
M=!!5_P#&:Z#KTG(B8\#.SCQ;(9/C)QT3.'B=/",B(<O_`*F+G]>*8/Y_P$.N
M5Y=:G,K=.+$EJN'"1V$K42(D;!!804F:=@KVTU^,;WZU\78^91^YBYFZKR!]
MB&F\<)6=EF6'\6'%=I].SU)VJC7Y&Y2M0@;1;M!G(PAP:R\^^=6$K)FJL0XM
M&#,I4O`55A4^M?:'C./QG&F<\MM#E[>K/F('E`)`EKV?G'(^8Y:\>R7^/11E
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M^/UZ^EFG"AA3("=BAH``!W`=*1R]2%D[RM7K&I5/7X1>5_;P>S77('U\\^ZK
MI;^7TQKP$R1SLV-.)]V[DI!*H/J=?)1'+W<HY4%VO`Q%EI`&8E.H)FK1\HB0
M0212*3YN]S^$6IY%CG;-*6TY%P-+EU4%#S^)29'P$=%XMEWO\8^V^=Q82=I/
MX[3%+G:-DT[D=J5OW#;;A*:%J&A2SF?L]IG5SO'"SEZ8521\:583$BJ_%)&!
MNQ8MP3;-&J9$R%``Z^@;#&VF&LVL=C6TL-,H"?+J9"I)[S,Q`;RZ>R3BKAU2
M@I1/7X0V[]O[S-U?BE[&<#H%1GY4<EY-Z%`XOK.<_=*GK4Y^LE#1-7N240)@
M:M[539]1NLB^3*#@S,7#<YC)*"4(3[H\=M<[Q&ZR#Z$_=V*-Z%R\\A4I)U5/
MM/\`H(WO$K^YL\FFR3-3:]22?RC<_P"Y8YGZIR#]AVG<<Y>=EF6'<5WT)2:7
MGA'#A"`D+@]JD'8;AH,S&E%-K*S\B]G19M'"I51:1[1,B/@*JHJ:KVAXU9XO
MC#.<4AMR[OE2W*2"I`!(DD_#NK6/>89;(.Y'[)9E;MKD)4G03GXPA'.K_>L@
MO%3U'*+9-Y]I-$EF<_4+K5WZL5.P4Q'N"N6KMNZ0.05$S'3*19`X&1<I"8BI
M#D,8!ZE?X>TRK:\??)*V'II"29A--8C#5X[87?W5GN2K>*;C(Z1]@3UY<C)G
MEQP?XN\DK+'H1=GU[':C:[4R:IE19DM2C+[&S+,$2@!4(]W.LG"S<@?Z$5"E
M_EU\)\EQ*<%G[O$(,T,/*2/#4?0QW?'7#EW8M7#O]Q:`3$RNM'&;$,.2W$GC
MAR<L=9L6A+O:OLV+(.9W/]GRZ^O<QW;'XJ:36(_6A[M7'K68:5*=(S6!U'R9
M'4(]!,PJMU!*(AM,9F<AB6UVUNO?8.KW.,N#>VLRD/*=)#LD>^,6XM&[B2B2
MEU.BA0CNC6$?ZU^.E]0:SVZ7;8.9ISQ9?T5.<C--)H$13&KTS1ZG8<T@:I%U
M"AUNS.0:(&)86<=^=?&7Q3>`F<Y39PY/DV)'&AJR,ZEA.PJF")*,R2)&4M.T
M1;^P:6@"X)<4#,$]/")%[]1^,_(2FVCC+R%+F5\J^BLF\)8\KMT[#IR4T5V=
M-Y%&9Q7YDTL#&80=))NH]VT%)X@NF15`Y3E*8-+CKJYQ=PBZLW%)N$&BI]M2
M%#10/4$2.D9;[35TTMBX2%,J&G9WB(G0WJHQJ-@6-%N/(+FEK.&PZ2#='C_K
M7)BT6C(W4%'^'V=7M*!649<[M3&2*!$QBIV;D6"Z!/C<)JIB8H[U[E%XZXJX
M0Q9MWJYS=0R`N9_D*R![P!\ZQA?XUG:EO<YZ2)23N,J=OX$3G5+0]5I$S2:'
MH:4=%MVC.#/+XQ<(=E-U)!J9(6C.(D8,7Z=>4*V:@B0@)E\$!$I`+]!".M.*
M;<]9<G%S).X;IDZZ_.-@`$IVIH)1$[BKZ\>,_`1&[+XQ9=3KM3TBSREFO56T
MC9K#=:+9[[=%&D?)6F1CKP[?I!:["N5))11)5,7BIP`Y%#"7M(\]RO*\C](Y
M(,EUAI+:%(0$*"$Z"8[(Q+:R9M04MS*%3W`R,Y]337IX1Y'%OUG\9>&%^NUX
MXUCJN9Q.AV2?MMHR./UFYR&%N+!8E5EG4A&9/+2+ZK5]=FJN/VIF"38R)2D)
MW,F0I`9GEF6Y`RVWEO1==:2$ASTTAP@```K&M`(IMK!BS<*[?<E)_C.8_*,5
M6]?O&A?4])LW'78-;XMZ!:9D;#M-9XH;)&T^NV6U2/U/:[SCDK%W:@1%ODR%
M'YI1O"Q[]X(B9550WXNJ$<GOUVZ+;(-VUXVTG:@O-A2D)[`H$*/_`*B?A%MS
M&,J67&U.-K/]"B/I&YL`X-8'QKMUPUFN-;9>]OOD>VB[]R$VRYS.I;/8Z]'#
M\K.N+7>T+K#7:>P.7Y"1$0C&Q1#!Y_!Y`!NL'(YK(9)E-FZ4(QR-&4)"$3[9
M#_69B_:V;%LHN56^?Y*,U?/K'H['P@R/3M]I_+<VL;VKH]8A)J&H,M4]MFV=
M&AJ3<'<-)V2LPE4C?DJCVKVAU`,57)5D7)U1:HB"H?&3QNLYM]BP7C4LVYME
MR*IHF24Z&<]8.6B'+E-T5+"TB0`(E^7^L;DY'X3B?*+)+MQFWJ'A;=0=@K4O
M!2U3D';=K+/&2)$U33-:$3_?LYRL.U&[QK(-BBJQ=$25`0'MWPL=DK[%7K>1
MLW"B[:4%)4*5GU[010B+SK++[)8>2%(-?CK.-LT>HQF?TJH4.$4=JPM)J\!4
M8A606*X?J1=;BFD-'G?.")HD7>&:,B"J<"$`Y^X@4._8+%P^Y<W"[EVKKBRH
M^*B2?J8];0&T!M/[4@`>`TC*>K,5Q3E]^GH&VGEAM<GS5X5,X*TZ+;(.$B]J
MQ27EXVK25ID:K%(PT-?*!.RZK.OKRZ]?8MF<C&O7#05S-4ED%C*'43'N_M?[
MF8[!6R<%R(N)M$JW-.`;DHF?VK&H$S,$3I.<0CDW''<@?NK&0?G,TJ>E(0EQ
M._;<^R_D3I$3`:OD3_BSER,JW3O&D:A(UP\JPB$SD._"DTJ%FY:8M4XLB!B-
M!4*VC@5[&5<%*`E'I6>]W.*XO'J7:/&\OYJ+:6A.1-/,H@!(KWGNB,V'$LK<
MW"?NBI#*==PU\)&+I7L6],>8<OO7;F/"O*I%EF<]QCBZHIQGM4T@J^CXJ3IU
M94JBD-<S,$@>+PM\A%E$Y1PW(*R3PZ;LJ:@H_$?YYXOSS(8/E#N>NPI:+E1#
MVTU*5&<Q/^G21^?6)[DL"U>8A.-:5M"!3Q[Z]37Q[HHL/OV^?MYC-&+F@</Y
MV0=F=E:M[K%WG.5LM40%04_S(]V4LR#9HP`@>?BL@D[\?H*`'_#U],)]S^`J
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ME(E)`ZZUK$*R'%<@PZ39I]1DF8I(B?;6&Q^BC]O7O^*<A:1S1YR049G;C*%W
M,]C>&)3,59;2YO+J,<1\?>;^^K[U]!P#.K(/EE&$:DX<NUG_`,:R_P`)$2D5
M@WN7[H8_(6#F`XVI;K3PVN.2VHVBLA.IGI/Y5TWW'N./6SZ,A=G8M*:(E7KJ
M9_&-I^_+T![7RMVN3YJ\+&D):]!MT'"1NU8G*RL76)2S2M6C$8:)OU`G)==E
M7UY5U`,6S21C'KAH98[5-=!4ZBBB0XOM=[FV&"M48+D7J)M$JW-N`;DHF?VJ
M`J*UF`>^*^3\;=R*S=69'J3F1+N`I"'.)'[;GV6\A](B(#6,C?\`%C+$95)&
M[Z3J,E7#R[&'3,0S\*52H69E)FS3KA$#)LS'*VC@5$#JN"E#L/3\W[N<2Q5@
MMRP?-[?J*MB4`^4D=5$2E]>Z(U8\4R5R\&KA'I,`@DJU/A'TL,-QVD<>\;R_
M#,VC31-"R.BUG/:DP4.51PE!U6*;1#%1XL0I"N'[I)K\KA7L'RKG.8?J/7R+
M?7K^2O';^Z.ZX>65*/>3/Z:1U6W81;,(81^U"0/EU^,;4ZQ(O0HGD[P[V_9^
M1>U7BBV=_G]3N.`47(K&[05:*?\`)M(<+Z'*WFE0I$W!7,);6\DG#I-9%R";
M=)I(.R`(B8>R$,)XTU2>HO'?"Z5:8P(2RU+(\\K<_#@JV7"+F86J14=)1X+L
MU5FBWVCQN=/R2.9,WCW*(AVZ0B$+K'-+C_8!>M3<YE:)G.[;-XXI%6>,J."V
M*!(2NY\2O2DG-6.\R)=8IP5Z8$J@!740.M\0&[&'I"&96!NN]K\VT;I"JY=1
M$FV;H@)0%1==DNDDGW$P%#S.<`^H@`=_J/2$*OX$<?-+SBYT6QV?$2XBPH_%
MF&Q6XK+/*-]]JFB-[@RG_P!4`RH\M+"[CH2-9K)IOY0R;U0[XQ"I@4#FZ0B8
M7,7/[5IF,MZQ3H-2PS)-7PRPFCDEV;<Y8FJ;#2;)./\`Y'R[=#QC(>+7<&+Y
M>9@3$"@)A`!0B4IN_;^`CV$![!V$>P#W_GTA"V>'N,6C,+6TA+GQGB*_:Z8G
ML"<[R>&S551YHI+[I3JV1#2'90R[VWV9&:BG""[]6>!H,6X9E12!43]RH1)[
ME;'ZI/X-?ZAB\4$CH=[8-Z'$.EI%O%,J\QM[QO!6&V/WZYRJMVE:K[UTZ[H$
M6="HF4$DCG[%%"->\(<YTK&,JD\8T&K,*[%9G<IJ*RQ:$L)K/`N\OF"HV*N1
MD9*O&L7.."U!64<1!A?,FJHE:$$I1)V-TA'K.1T9H\+R!XW;%2LAMFN0^>5K
M<X2QQM,D::PFH]Q>HZC-X14A;I9:PR7;KJ0BX'^-8QR^(#V[=(1-&,=+OHV/
M>NF#F*<O&35TXBWIFYWD:NX03658.SLUG+0[EF<XIJ"DHHF)RCXF,7L(H1YW
M2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'
- -2$'2$'2$'2$'2$?_V3\_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
